Treatment of Polycystic Liver Disease with Hepatomegaly (Symptomatic, No Cyst Hemorrhage or Infection)
Symptomatic polycystic liver disease presenting with hepatomegaly requires a targeted treatment approach when cyst hemorrhage and cyst infection have been excluded. The primary goal is to reduce the volume of hepatic cysts and relieve the burden of symptoms.
Clinical scenario
Symptomatic polycystic liver disease with hepatomegaly, in the absence of cyst hemorrhage and cyst infection. In this setting, the treatment objective is reduction of hepatomegaly volume rather than management of acute cyst complications.
Treatment approach (partial — full regimen available below)
Medical treatment involves a somatostatin analogue to reduce the volume of hepatic cysts — the specific agent and management algorithm are detailed in the full structured protocol.
Complete regimen, agent selection, and targets not shown here ›
References
DOI: 10.1016/j.jviscsurg.2018.07.004
In symptomatic patients, the treatment goal is to reduce the volume of hepatomegaly, except for the two special cases of hemorrhage and infection.
Medical treatment aims to block cAMP and relies on somatostatin analogues such as lanreotide, octreotide or pasireotide, which have demonstrated a certain effectiveness in reducing the volume of hepatic cysts.
View source ↗